|Title:||Treatment of emesis with morpholine tachykinin receptor antagonists|
|Abstract:||Substituted heterocycles of the structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma, emesis and nausea.|
|Inventor(s):||Dorn; Conrad P. (Plainfield, NJ), MacCoss; Malcolm (Freehold, NJ), Hale; Jeffrey J. (Westfield, NJ), Mills; Sander G. (Woodbridge, NJ)|
|Assignee:||Merck & Co., Inc. (Rahway, NJ)|
Patent Claim Types:|
see list of patent claims
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.